<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02154516</url>
  </required_header>
  <id_info>
    <org_study_id>2011-ODHH166</org_study_id>
    <nct_id>NCT02154516</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System</brief_title>
  <official_title>A Consecutive Series Pilot Study Evaluating the Safety and Effectiveness of a New Hard-on-Hard Total Hip Replacement System in Patients With Non-inflammatory Arthritis With a Standard THA Metal Ion Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the early and long term safety and efficacy of the&#xD;
      hard-on-hard total hip replacement system (R3 ODH-ODH utilization) in patients with&#xD;
      non-inflammatory arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 4, 2011</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revision Rate</measure>
    <time_frame>Up to 10 Years</time_frame>
    <description>Reoperations that led to removal or replacement of any of the acetabular or femoral components.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 10 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metal Ion Concentration in Whole Blood</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harris Hip score</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Disability and Osteoarthritis Outcome Scores (HOOS)</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic measures</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Assessment of bone loss, radiolucencies, subsidence, and heterotopic ossification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcomes-Surgical blood loss</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Measured in ml blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcomes -Length of hospital stay</measure>
    <time_frame>Hospital admission to discharge</time_frame>
    <description>Measure of days spent in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcomes-Operative time</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Operative time - first incision into skin to time when last suture is applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic outcomes - Re-hospitalisations</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Re-hospitalisations-number of re-admissions to hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Arthritis, Degenerative</condition>
  <arm_group>
    <arm_group_label>Control Total Hip Replacement Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:&#xD;
R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem&#xD;
OXINIUM heads on polyethylene liners or&#xD;
Ceramic heads on ceramic liners (all uncemented components)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Hard-on-Hard Total Hip Replacement Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:&#xD;
R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem&#xD;
R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)&#xD;
R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)&#xD;
Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ODH Hip System</intervention_name>
    <arm_group_label>Control Total Hip Replacement Device</arm_group_label>
    <arm_group_label>Investigational Hard-on-Hard Total Hip Replacement Device</arm_group_label>
    <other_name>Total Hip Replacement</other_name>
    <other_name>THR</other_name>
    <other_name>Total Hip Arthroplasty</other_name>
    <other_name>THA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 21 years old&#xD;
&#xD;
          -  Skeletally mature&#xD;
&#xD;
          -  Requires primary, unilateral total hip arthroplasty due to degenerative join disease&#xD;
&#xD;
          -  Preoperative Harris Hip Score of less than or equal to 70&#xD;
&#xD;
          -  Meets an acceptable preoperative medical clearance and is free or treated for&#xD;
             conditions that would pose excessive operative risk&#xD;
&#xD;
          -  Given consent to participate in the study&#xD;
&#xD;
          -  Able to understand the purpose of the study, his/her role, and is available for&#xD;
             follow-up&#xD;
&#xD;
             10 year extension:&#xD;
&#xD;
               -  Subject has completed the 2 year primary study&#xD;
&#xD;
               -  Subject has signed an Independent Ethics Committee (IEC) approved Informed&#xD;
                  Consent Form agreeing to participate in the extension study after the nature,&#xD;
                  scope and possible consequences of the study have been explained in an&#xD;
                  understandable form&#xD;
&#xD;
               -  Subject is able to fully understand the purpose of the study, his/her role as a&#xD;
                  participant in the study, and plans to be available through ten years&#xD;
                  post-operative follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis with high risk of Total Hip Arthroplasty (THA) failure&#xD;
&#xD;
          -  Requires bilateral THA&#xD;
&#xD;
          -  Requires revision of a prior hip replacement&#xD;
&#xD;
          -  Active infection or sepsis&#xD;
&#xD;
          -  History of local hip infection&#xD;
&#xD;
          -  Known metastatic or neoplastic disease&#xD;
&#xD;
          -  Conditions that may interfere with THA survival or outcomes&#xD;
&#xD;
          -  Need for structural bone grafts to support the implant&#xD;
&#xD;
          -  Contralateral lower extremity condition&#xD;
&#xD;
          -  Has other joint replacements or plans for other joint replacements within 2 years&#xD;
&#xD;
          -  Systemic steroid therapy within 3 months prior to surgery&#xD;
&#xD;
          -  Life expectancy less than 2 years&#xD;
&#xD;
          -  Intra-articular therapy within 6 months of enrollment&#xD;
&#xD;
          -  Female of child-bearing age not using contraception&#xD;
&#xD;
          -  Inadequate bone stock to support the device&#xD;
&#xD;
          -  Moderate to severe renal insufficiency&#xD;
&#xD;
          -  Emotional or neurological condition that would pre-empt ability or willingness to&#xD;
             participate in the study&#xD;
&#xD;
          -  BMI &gt;40&#xD;
&#xD;
          -  Above the knee amputation of the contralateral or ipsilateral leg&#xD;
&#xD;
          -  Known allergies to the components of the devices&#xD;
&#xD;
          -  Entered into another investigational study&#xD;
&#xD;
          -  Is a prisoner&#xD;
&#xD;
             10 year extension:&#xD;
&#xD;
             â€¢ In the opinion of the surgeon, the subject's health, safety or well-being may be&#xD;
             compromised or harmed by continuation in the extension phase or participation may not&#xD;
             be in the subject's best interests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Baker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Entabeni Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes de Beer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zuid Afrikaans Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Entabeni Hospital</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuid Afrikaans Hospital</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

